BCRX Stock Chart & Stats
$182.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$118.00 - $197.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)231.00
Market Cap
$41.51B
Enterprise Value$2.93K
Total Cash (Recent Filing)$239.25M
Total Debt (Recent Filing)$858.08M
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Aug 05, 2026EPS Estimate
2.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding254,162,660
10 Day Avg. Volume53
30 Day Avg. Volume231
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-13.74
Price to Sales (P/S)1.87
P/FCF Ratio5.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$383.25Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained, large positive operating and free cash flow provides durable funding for commercialization, pipeline advancement, and M&A without immediate equity raises. This cash conversion covers accounting losses, supports liquidity and strategic optionality while reducing reliance on external capital over the next several quarters.
Robust ORLADEYO Commercial ExecutionA marketed, growing product with steady prescriber additions (~60/month) and ~60% one-year retention underpins predictable recurring revenue. Management's maintained full-year ORLADEYO guidance shows durable market demand and commercial scale that can fund operations and provide a platform for future launches.
De-risking Via Licensing And Pipeline ProgressPartnering European rights transfers commercialization burden, delivers non-dilutive upfront cash, milestone upside and royalties, and preserves U.S. focus. Combined with Phase 3 enrollment progress, this strategy reduces capital intensity and preserves upside while improving pro forma liquidity and execution bandwidth.
Bears Say
Persistent Negative Shareholders' EquityNegative equity reflects cumulative losses and constrains balance-sheet resilience; it can limit access to favorable financing, heighten refinancing and covenant risk, and reduce strategic flexibility. Even with lower debt, the fragile capital base raises medium-term funding and governance considerations.
Acquisition Accounting, Dilution And Added LeverageThe large GAAP charge is non-cash but materially increases reported losses; concurrent share issuance dilutes existing holders and the new credit facility raises financial leverage. Together these factors alter capital structure and may constrain flexibility and per-share economics over the medium term.
Competitive Pressure And Pediatric Operational RiskRising therapeutic competition and a manufacturing delay for pediatric pellets risk slower conversion from free-to-paid use and could pressure market share or pricing over time. Operational setbacks plus increased rival options create structural commercial headwinds that could blunt long-term growth momentum.
BCRX FAQ
What was BioCryst Pharmaceuticals’s price range in the past 12 months?
BioCryst Pharmaceuticals lowest stock price was $118.00 and its highest was $197.50 in the past 12 months.
What is BioCryst Pharmaceuticals’s market cap?
BioCryst Pharmaceuticals’s market cap is $41.51B.
When is BioCryst Pharmaceuticals’s upcoming earnings report date?
BioCryst Pharmaceuticals’s upcoming earnings report date is Aug 05, 2026 which is in 10 days.
How were BioCryst Pharmaceuticals’s earnings last quarter?
BioCryst Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$52.176 earnings per share for the quarter, missing the consensus estimate of $0.77 by -$52.947.
Is BioCryst Pharmaceuticals overvalued?
According to Wall Street analysts BioCryst Pharmaceuticals’s price is currently Undervalued.
Does BioCryst Pharmaceuticals pay dividends?
BioCryst Pharmaceuticals does not currently pay dividends.
What is BioCryst Pharmaceuticals’s EPS estimate?
BioCryst Pharmaceuticals’s EPS estimate is 2.7.
How many shares outstanding does BioCryst Pharmaceuticals have?
BioCryst Pharmaceuticals has 254,162,660 shares outstanding.
What happened to BioCryst Pharmaceuticals’s price movement after its last earnings report?
BioCryst Pharmaceuticals reported an EPS of -$52.176 in its last earnings report, missing expectations of $0.77. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioCryst Pharmaceuticals?
Currently, no hedge funds are holding shares in MX:BCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$383.25 (― Downside)
$383.25 (― Downside)
Blogger Sentiment
Bullish
MX:BCRX Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.12%
Trailing 12-Months
Company Description
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
BCRX Stock 12 Month Forecast
Average Price Target
$383.25